Commentary|Videos|July 30, 2026

How Clinicians Should Choose Among Bladder-Preserving Therapies for NMIBC

Name: How Clinicians Should Choose Among Bladder-Preserving Therapies for NMIBC
Uploaded: 2026-07-30T14:04:17.334Z
Duration: 3 min 32 s
Description: In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, oncology pharmacist at William Beaumont University Hospital, discussed the growing range of bladder-preserving therapies available for patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).

Author(s)Ryu Kariyawasam-Chavez, Content Associate

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses how efficacy, safety, cost, dosing schedules, prior treatment, and patient preferences can guide selection among bladder-preserving therapies for BCG-unresponsive NMIBC.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, oncology pharmacist at William Beaumont University Hospital, discussed the growing range of bladder-preserving therapies available for patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).